Cell子刊：卡替医疗的“三合一”T细胞疗法，显著延长晚期胆道癌患者生存期

Core Viewpoint - CAR-T cell therapy has shown clinical success in hematological malignancies, but its efficacy in solid tumors remains significantly lower, highlighting the challenges faced by T cell therapies in this area [2][3]. Group 1: Challenges in T Cell Therapy for Solid Tumors - Three key obstacles for T cell therapy in solid tumors include: 1) antigen heterogeneity; 2) tumor microenvironment suppressing T cell function; 3) difficulty in cultivating sufficient non-exhausted T cells in vitro [3][5]. Group 2: Research Findings on ScTIL - A study published in Cell Reports Medicine introduced a "three-in-one" strategy to produce super circulating TIL-like cells (ScTIL) for the treatment of biliary tract cancer, demonstrating safety and significantly extending survival for late-stage patients [3][5][9]. - The ScTIL production involves: 1) isolating PD-1+ T cells from patient peripheral blood; 2) modifying these T cells with enhanced receptors to counteract tumor microenvironment suppression; 3) co-expressing amplification factors and anti-CD19 CAR for rapid in vivo expansion [5][8]. - In a clinical trial with 10 late-stage biliary tract cancer patients, ScTIL treatment resulted in a median overall survival (OS) of 18.3 months, surpassing the standard treatment OS of approximately 12 months [5][8]. Group 3: Implications for Future Treatments - The study indicates that ScTIL significantly improves survival rates for late-stage biliary tract cancer patients, suggesting it as a promising therapy for solid tumors and offering new hope for cell therapy in this domain [9].